Stereotactic body radiation therapy (SBRT), also called stereotactic ablative radiotherapy (SABR), is a type of radiation therapy in which a few very high doses of radiation are delivered to small, well-defined tumors. The goal is to deliver a radiation dose that is high enough to kill the cancer while minimizing exposure to surrounding healthy organs. Barbara Pool is one of six lung cancer patients per day who go through stereotactic body radiation therapy and she is the 1000th patient to...

New cancer research for stage 1 lung cancer is being investigated at The University of Texas MD Anderson Cancer Center. It’s led by Jack Roth, M.D., professor in the Department of Thoracic and Cardiovascular Surgery. This clinical trial called STARS (Stereotactic Radiation Therapy Verses Surgery) compares a new type of radiation treatment with a traditional surgery approach. Roth describes this promising new treatment and explains how lung cancer patients may get involved.

Results from national clinical trial mobilizes a team of experts to develop Lung Cancer Screening Program. For appointment contact AskMDAnderson 877-MDA-6789 https://www2.mdanderson.org/sapp/contact/selfreferral/index.cfm

Dr. Stephen Swisher discusses lung cancer and MD Anderson's approach to treating the disease. His advice to patients with lung cancer is not to rush into a treatment program right away; instead, they should research various options and decide on the best plan, with their medical team.

Dr. Edward S. Kim leads the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program at MD Anderson and offers an update on lung cancer research. Dr. Kim also talks about the importance of continued philanthropic support for this underfunded research.

Dr. Cox explains the outcomes of proton therapy with concurrent chemotherapy, how lung cancer patients typically tolerate treatment and what the future holds for lung cancer patients being treated with proton therapy at MD Anderson.

For more information on MD Anderson's Proton Therapy Center you can visit the website at http://mdanderson.org/proton

Th17 sets off a chain of events that ends with custom-made killer T cells destroying tumors.

Cancer manages to suppress or elude the body's immune system to survive and grow. Scientists at The University of Texas M. D. Anderson Cancer Center show this week in the journal Immunity how the helper T cell Th17 awakens the immune system to attack cancer. Senior author Chen Dong discusses the findings and their potential application for patients.